BHC - Bausch Health Projected Sales Volume

Bausch Health - graphic logo of issuer BHC

This chart on GURU.Markets displays the projected sales revenue level, where 11.11 represents the current value. Bausch Health Companies (BHC) is expanding its holding through the consolidation of ophthalmology assets and partnerships with networks. Stable income is driven by physician loyalty to established dermatological brands. However, a critical debt load and patent disputes regarding Xifaxan pose serious financial threats.

BHC - Bausch Health Corp Company Projected Revenue over the range 07/04/2022 - 11/16/2026

Analytical breakdowns for Bausch Health Companies

- stock value and consensus price forecast:
Basic company analysis:Bausch Health Companies Inc.
Product sample of Valeant Pharmaceuticals

For the long-term investor, the reliability of Bausch Health Companies (BHC) is determined by its ability to maintain market share in the dermatology and gastroenterology segments while reducing debt. This metric aggregates market forecasts and current contracts; therefore, the trend in the company's planned sales allows for an assessment of the fundamental stability of revenue amid fierce competition for patented drugs, signaling the stability of the issuer's operating cash flow.